Operational Milestone #5 (final)
We are pleased to communicate in this final report that despite limitations imposed by COVID-19, all milestones have been met and finished on time. The necessary cell testing is complete and we have obtained approval from the FDA and all local university committees to begin human clinical trials using our unique stem cell product for the repair of spina bifida before birth. A team of doctors and nurses has been assembled and we have submitted the necessary paperwork to conduct a first in human clinical trial. Our goal is to demonstrate thte safety of our stem cell product and to show preliminary improvement of the paralysis associated with this devastating disease.